ACER THERAPEUTICS INC (ACER) Fundamental Analysis & Valuation

NASDAQ:ACER • US00444P1084

Current stock price

0.9 USD
+0.03 (+3.41%)
At close:
0.8005 USD
-0.1 (-11.06%)
After Hours:

This ACER fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ACER Profitability Analysis

1.1 Basic Checks

  • ACER had negative earnings in the past year.
  • In the past year ACER has reported a negative cash flow from operations.
ACER Yearly Net Income VS EBIT VS OCF VS FCFACER Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M

1.2 Ratios

  • ACER's Return On Assets of -225.71% is on the low side compared to the rest of the industry. ACER is outperformed by 92.72% of its industry peers.
Industry RankSector Rank
ROA -225.71%
ROE N/A
ROIC N/A
ROA(3y)-141.6%
ROA(5y)-120.76%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ACER Yearly ROA, ROE, ROICACER Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 200 -200 400 -400 600 800

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ACER so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACER Yearly Profit, Operating, Gross MarginsACER Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. ACER Health Analysis

2.1 Basic Checks

  • ACER does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ACER has more shares outstanding than it did 1 year ago.
  • The debt/assets ratio for ACER is higher compared to a year ago.
ACER Yearly Shares OutstandingACER Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M
ACER Yearly Total Debt VS Total AssetsACER Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M

2.2 Solvency

  • ACER has an Altman-Z score of -25.07. This is a bad value and indicates that ACER is not financially healthy and even has some risk of bankruptcy.
  • ACER has a Altman-Z score of -25.07. This is amonst the worse of the industry: ACER underperforms 91.75% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -25.07
ROIC/WACCN/A
WACC9.13%
ACER Yearly LT Debt VS Equity VS FCFACER Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M

2.3 Liquidity

  • ACER has a Current Ratio of 0.19. This is a bad value and indicates that ACER is not financially healthy enough and could expect problems in meeting its short term obligations.
  • ACER's Current ratio of 0.19 is on the low side compared to the rest of the industry. ACER is outperformed by 97.09% of its industry peers.
  • ACER has a Quick Ratio of 0.19. This is a bad value and indicates that ACER is not financially healthy enough and could expect problems in meeting its short term obligations.
  • ACER has a Quick ratio of 0.19. This is amonst the worse of the industry: ACER underperforms 96.12% of its industry peers.
Industry RankSector Rank
Current Ratio 0.19
Quick Ratio 0.19
ACER Yearly Current Assets VS Current LiabilitesACER Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. ACER Growth Analysis

3.1 Past

  • The earnings per share for ACER have decreased strongly by -88.64% in the last year.
  • ACER shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)-88.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-74.19%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

  • The Earnings Per Share is expected to grow by 35.01% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y55.45%
EPS Next 2Y44%
EPS Next 3Y35.01%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ACER Yearly Revenue VS EstimatesACER Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2021 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M
ACER Yearly EPS VS EstimatesACER Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -5 -10 -15 -20

More info and screens

Find the best growth stocksShow best growing peers

1

4. ACER Valuation Analysis

4.1 Price/Earnings Ratio

  • ACER reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ACER. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACER Price Earnings VS Forward Price EarningsACER Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACER Per share dataACER EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1 -1.5

4.3 Compensation for Growth

  • ACER's earnings are expected to grow with 35.01% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44%
EPS Next 3Y35.01%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ACER Dividend Analysis

5.1 Amount

  • No dividends for ACER!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

ACER Fundamentals: All Metrics, Ratios and Statistics

ACER THERAPEUTICS INC

NASDAQ:ACER (11/8/2023, 8:19:05 PM)

After market: 0.8005 -0.1 (-11.06%)

0.9

+0.03 (+3.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-15
Earnings (Next)03-25
Inst Owners1.19%
Inst Owner Change0%
Ins Owners0.02%
Ins Owner Change0%
Market Cap22.01M
Revenue(TTM)N/A
Net Income(TTM)-26.24M
Analysts80
Price Target1.53 (70%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.22%
Min EPS beat(2)-43.08%
Max EPS beat(2)55.52%
EPS beat(4)2
Avg EPS beat(4)8%
Min EPS beat(4)-51.19%
Max EPS beat(4)70.76%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-86.36%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-6.62%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-16.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.66
EYN/A
EPS(NY)-0.74
Fwd EYN/A
FCF(TTM)-1.24
FCFYN/A
OCF(TTM)-1.24
OCFYN/A
SpS0
BVpS-0.69
TBVpS-1
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -225.71%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-141.6%
ROA(5y)-120.76%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score0
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 259.19%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.19
Quick Ratio 0.19
Altman-Z -25.07
F-Score0
WACC9.13%
ROIC/WACCN/A
Cap/Depr(3y)116.99%
Cap/Depr(5y)196.86%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-88.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-74.19%
EPS Next Y55.45%
EPS Next 2Y44%
EPS Next 3Y35.01%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-91.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-15924.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-22323.8%
OCF growth 3YN/A
OCF growth 5YN/A

ACER THERAPEUTICS INC / ACER Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ACER THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 0 / 10 to ACER.


What is the valuation status of ACER THERAPEUTICS INC (ACER) stock?

ChartMill assigns a valuation rating of 1 / 10 to ACER THERAPEUTICS INC (ACER). This can be considered as Overvalued.


How profitable is ACER THERAPEUTICS INC (ACER) stock?

ACER THERAPEUTICS INC (ACER) has a profitability rating of 0 / 10.


What is the earnings growth outlook for ACER THERAPEUTICS INC?

The Earnings per Share (EPS) of ACER THERAPEUTICS INC (ACER) is expected to grow by 55.45% in the next year.